Drugs / MH-001
last change Jun 2025 re-read 3 minutes ago

MH-001

Investigated by
PrimeVigilance Ltd., UK · Syneos Health · Vespina Lifesciences Inc.

Trials 1

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06780254 Sep 2024 → May 2025 — Vespina Lifesciences Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MH-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06780254 ↗